AELIS FARMA SAS (AELIS.PA) Stock Price, Forecast & Analysis
EPA:AELIS • FR0014007ZB4
AELIS.PA Key Statistics, Chart & Performance
The current stock price of AELIS.PA is 1.45 EUR. In the past month the price increased by 16.94%. In the past year, price decreased by -38.56%.
AELIS.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AELIS.PA. When comparing the yearly performance of all stocks, AELIS.PA is a bad performer in the overall market: 71.75% of all stocks are doing better.
AELIS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA. Both the profitability and financial health of AELIS.PA have multiple concerns.
AELIS.PA Financial Highlights
Over the last trailing twelve months AELIS.PA reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.61% | ||
| ROE | -134.05% | ||
| Debt/Equity | 0.74 |
AELIS.PA Forecast & Estimates
9 analysts have analysed AELIS.PA and the average price target is 11.22 EUR. This implies a price increase of 673.79% is expected in the next year compared to the current price of 1.45.
For the next year, analysts expect an EPS growth of -131.58% and a revenue growth -52.86% for AELIS.PA
AELIS.PA Ownership
AELIS.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 27.9 | 43.368B | ||
| 1AE | ARGENX SE | 27.78 | 43.306B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.074B | ||
| ABVX | ABIVAX SA | N/A | 7.703B | ||
| 2X1 | ABIVAX SA | N/A | 7.695B | ||
| GXE | GALAPAGOS NV | N/A | 1.887B | ||
| GLPG | GALAPAGOS NV | N/A | 1.871B | ||
| IVA | INVENTIVA SA | N/A | 984.579M | ||
| 6IV | INVENTIVA SA | N/A | 978.821M | ||
| NANO | NANOBIOTIX | N/A | 972.597M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About AELIS.PA
Company Profile
Aelis Farma SA is a biopharmaceutical company. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 26 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
Company Info
AELIS FARMA SAS
1 Rue Lafaurie de Monbadon
Bordeaux NOUVELLE-AQUITAINE FR
Employees: 28
Phone: 33557573770
AELIS FARMA SAS / AELIS.PA FAQ
What does AELIS do?
Aelis Farma SA is a biopharmaceutical company. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 26 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
Can you provide the latest stock price for AELIS FARMA SAS?
The current stock price of AELIS.PA is 1.45 EUR.
Does AELIS stock pay dividends?
AELIS.PA does not pay a dividend.
What is the ChartMill rating of AELIS FARMA SAS stock?
AELIS.PA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does AELIS FARMA SAS belong to?
AELIS FARMA SAS (AELIS.PA) operates in the Health Care sector and the Biotechnology industry.
Should I buy AELIS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AELIS.PA.